A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Inclusion Criteria

• •1. R/R B-NHL with measurable (≧1.5cm) lesions confirmed by pathological immunohistochemistry or flow cytometry ( meeting any of the following conditions):
• •A.The lesion shrinkage \<50% or disease progression after 4 courses of standard first-line treatment or 2 courses of two-line treatment (primary refractory disease) B. Progress disease as the best response after hematopoietic stem cell transplantation C.Progress disease or stable disease as the best response to most recent therapy regimen
• •2. Age ≥ 18 years
• •3. The Eastern Cooperative Oncoloy Group (ECOG) physical condition score ≤ 2 points
• •4. The main organ functions need to meet the following conditions:
• •A.Left ventricular ejection fraction ≥50% B.Creatinine ≤132umol/l or creatinine clearance ≥60 ml/min C.ALT and AST≤2 upper limitation of normal D.SpO2 \> 90%
• •5. Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion
• •6. Expected survival exceeds 3 months
• •7. Written informed consent could be acquired